Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company ...

Merck MRK-1.35%decrease; red down pointing triangle & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics CDTX-0.22%decrease; red down pointing triangle in a move that ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year. Merck is paying $221.50 cash per share of Cidara, a San ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Merck said Friday it would buy Cidara Therapeutics, the maker of an ...

Oct 30 (Reuters) - Merck & Co (MRK.N), opens new tab posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus ...

Merck on Monday announced the groundbreaking of its new Virginia pharmaceutical manufacturing facility, a cornerstone of the company’s $70 billion U.S. investment strategy. The 400,000-square-foot ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. BERLIN — At a prime-time session on Saturday at a major cancer conference ...

Merck & Co. will build a $3 billion pharmaceutical manufacturing facility in Elkton that is expected to create 500 jobs, Gov. Glenn Youngkin and the company announced at a ceremonial groundbreaking ...

Keytruda continues to dominate, driving 50% of revenue, with new approvals and delivery methods strengthening MRK's oncology leadership. The company’s long-term outlook is also promising, with a full ...

Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.